ADEPT-4 Psychosis Associated with Alzheimer's Disease Research Study

About the ADEPT-4 Study

This study aims to evaluate the safety and efficacy of the investigational medicine, KarXT, for the treatment of psychosis associated with Alzheimer’s disease. 

The total duration of treatment is 14 weeks with an additional screening period and safety follow-up. All study-related visits, tests, and the study drug will be provided to you at no cost. In addition, you may be compensated for your time and reimbursed for study-related meals and travel.

Criteria for eligibility include: 

• Ages 55 to 90
• Diagnosis of mild to severe Alzheimer’s disease with moderate to severe psychosis (hallucinations and/or delusions)
• Have a caregiver that will be able to attend all visits, report on the participant’s status, oversee medication and treatment, and participate in some written study assessments

Additional study requirements to participate will apply. A study representative will discuss them with you.